| 1 | TREM2 deficiency reprograms intestinal macrophages and microbiota to enhance anti–PD-1 tumor immunotherapy | 13.5 | 35 | Citations (PDF) |
| 2 | CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses | 36.4 | 104 | Citations (PDF) |
| 3 | cDC1 Vaccines Drive Tumor Rejection by Direct Presentation Independently of Host cDC1 | 4.2 | 50 | Citations (PDF) |
| 4 | <i>Bcl6</i>-Independent In Vivo Development of Functional Type 1 Classical Dendritic Cells Supporting Tumor Rejection | 0.6 | 6 | Citations (PDF) |
| 5 | Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads | 7.6 | 115 | Citations (PDF) |
| 6 | Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen PredictionCell, 2020, 183, 818-834.e13 | 34.1 | 475 | Citations (PDF) |
| 7 | TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 ImmunotherapyCell, 2020, 182, 886-900.e17 | 34.1 | 556 | Citations (PDF) |
| 8 | cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity | 38.7 | 504 | Citations (PDF) |
| 9 | An Important Role for CD4
<sup>+</sup>
T Cells in Adaptive Immunity to Toxoplasma gondii in Mice Lacking the Transcription Factor Batf3 | 3.0 | 9 | Citations (PDF) |
| 10 | MHC-II neoantigens shape tumour immunity and response to immunotherapy | 38.7 | 786 | Citations (PDF) |
| 11 | Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity | 7.3 | 522 | Citations (PDF) |
| 12 | High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer TherapyCell, 2018, 175, 1014-1030.e19 | 34.1 | 366 | Citations (PDF) |
| 13 | Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma | 1.7 | 40 | Citations (PDF) |
| 14 | Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape | 4.2 | 271 | Citations (PDF) |
| 15 | Inflammatory monocytes require type I interferon receptor signaling to activate NK cells via IL-18 during a mucosal viral infection | 9.4 | 104 | Citations (PDF) |
| 16 | Novel non-canonical role of STAT1 in Natural Killer cell cytotoxicity | 5.5 | 17 | Citations (PDF) |
| 17 | NKG2D–NKG2D Ligand Interaction Inhibits the Outgrowth of Naturally Arising Low-Grade B Cell Lymphoma In Vivo | 0.6 | 24 | Citations (PDF) |
| 18 | Truncating Prolactin Receptor Mutations Promote Tumor Growth in Murine Estrogen Receptor-Alpha Mammary Carcinomas | 6.4 | 29 | Citations (PDF) |
| 19 | Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach | 4.2 | 102 | Citations (PDF) |
| 20 | Novel ERα positive breast cancer model with estrogen independent growth in the bone microenvironment | 1.7 | 8 | Citations (PDF) |
| 21 | Tumor neoantigens: building a framework for personalized cancer immunotherapy | 10.7 | 574 | Citations (PDF) |
| 22 | Selective Blockade of Interferon-α and -β Reveals Their Non-Redundant Functions in a Mouse Model of West Nile Virus Infection | 2.4 | 56 | Citations (PDF) |
| 23 | Abnormal Mammary Development in 129:STAT1-Null Mice is Stroma-Dependent | 2.4 | 9 | Citations (PDF) |
| 24 | Dual Requirement of Cytokine and Activation Receptor Triggering for Cytotoxic Control of Murine Cytomegalovirus by NK Cells | 4.4 | 48 | Citations (PDF) |
| 25 | Consensus nomenclature for CD8<sup>+</sup>T cell phenotypes in cancer | 5.5 | 131 | Citations (PDF) |
| 26 | Neoantigens in cancer immunotherapy | 36.4 | 4,436 | Citations (PDF) |
| 27 | Blockade of Interferon Beta, but Not Interferon Alpha, Signaling Controls Persistent Viral Infection | 15.3 | 170 | Citations (PDF) |
| 28 | Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer ProgressionCell, 2015, 162, 1229-1241 | 34.1 | 2,793 | Citations (PDF) |
| 29 | New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape | 5.3 | 1,322 | Citations (PDF) |
| 30 | Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy | 39.5 | 968 | Citations (PDF) |
| 31 | Programmable nanoparticle functionalization for<i>in vivo</i>targeting | 0.7 | 63 | Citations (PDF) |
| 32 | Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy | 4.1 | 319 | Citations (PDF) |
| 33 | Identifying the Initiating Events of Anti-<i>Listeria</i>Responses Using Mice with Conditional Loss of IFN-γ Receptor Subunit 1 (IFNGR1) | 0.6 | 63 | Citations (PDF) |
| 34 | Loss of DAP12 and FcRγ Drives Exaggerated IL-12 Production and CD8+ T Cell Response by CCR2+ Mo-DCs | 2.4 | 18 | Citations (PDF) |
| 35 | Opposing Roles for IL-23 and IL-12 in Maintaining Occult Cancer in an Equilibrium State | 0.6 | 103 | Citations (PDF) |
| 36 | Critical Role for Interferon Regulatory Factor 3 (IRF-3) and IRF-7 in Type I Interferon-Mediated Control of Murine Norovirus Replication | 3.7 | 81 | Citations (PDF) |
| 37 | Small-Animal PET of Steroid Hormone Receptors Predicts Tumor Response to Endocrine Therapy Using a Preclinical Model of Breast Cancer | 5.6 | 64 | Citations (PDF) |
| 38 | Anti–IFN-α/β Receptor Antibody Treatment Ameliorates Disease in Lupus-Predisposed Mice | 0.6 | 107 | Citations (PDF) |
| 39 | STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas | 4.9 | 177 | Citations (PDF) |
| 40 | Compensatory dendritic cell development mediated by BATF–IRF interactions | 38.7 | 399 | Citations (PDF) |
| 41 | Timing and Magnitude of Type I Interferon Responses by Distinct Sensors Impact CD8 T Cell Exhaustion and Chronic Viral Infection | 15.3 | 164 | Citations (PDF) |
| 42 | Cancer immunoediting by the innate immune system in the absence of adaptive immunity | 9.4 | 309 | Citations (PDF) |
| 43 | A dual function of <scp>NKG</scp>2<scp>D</scp> ligands in <scp>NK</scp>‐cell activation | 3.2 | 9 | Citations (PDF) |
| 44 | Type I interferon is selectively required by dendritic cells for immune rejection of tumors | 9.4 | 1,009 | Citations (PDF) |
| 45 | CD8α+ Dendritic Cells Are an Obligate Cellular Entry Point for Productive Infection by Listeria monocytogenes | 23.3 | 175 | Citations (PDF) |
| 46 | Natural Innate and Adaptive Immunity to Cancer | 30.0 | 1,874 | Citations (PDF) |
| 47 | Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion | 36.4 | 5,742 | Citations (PDF) |
| 48 | CXCR3 Enhances a T-Cell–Dependent Epidermal Proliferative Response and Promotes Skin Tumorigenesis | 0.6 | 41 | Citations (PDF) |
| 49 | Cancer Immunoediting of the NK Group 2D Ligand H60a | 0.6 | 28 | Citations (PDF) |
| 50 | A Temporal Role Of Type I Interferon Signaling in CD8+ T Cell Maturation during Acute West Nile Virus Infection | 4.4 | 104 | Citations (PDF) |
| 51 | TAK1 targeting by glucocorticoids determines JNK and IκB regulation in Toll-like receptor–stimulated macrophagesBlood, 2010, 115, 1921-1931 | 4.2 | 52 | Citations (PDF) |
| 52 | Interleukin 12 Stimulates IFN-γ–Mediated Inhibition of Tumor-Induced Regulatory T-Cell Proliferation and Enhances Tumor Clearance | 0.6 | 83 | Citations (PDF) |
| 53 | The Lymphotoxin LTα1β2 Controls Postnatal and Adult Spleen Marginal Sinus Vascular Structure and Function | 23.3 | 46 | Citations (PDF) |
| 54 | Immune-mediated dormancy: an equilibrium with cancer | 3.0 | 286 | Citations (PDF) |
| 55 | A Critical Role for Type I IFN in Arthritis Development following<i>Borrelia burgdorferi</i>Infection of Mice | 0.6 | 90 | Citations (PDF) |
| 56 | Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis | 7.6 | 283 | Citations (PDF) |
| 57 | HIF-1α regulates epithelial inflammation by cell autonomous NFκB activation and paracrine stromal remodelingBlood, 2008, 111, 3343-3354 | 4.2 | 139 | Citations (PDF) |
| 58 | Prolongation of Cardiac and Islet Allograft Survival by a Blocking Hamster Anti-Mouse CXCR3 Monoclonal Antibody | 1.2 | 71 | Citations (PDF) |
| 59 | IL-12 Stimulates Interferon-Gamma Mediated Inhibition of Tumor-Induced Regulatory T Cell Proliferation and Enhances Tumor ClearanceBlood, 2008, 112, 2558-2558 | 4.2 | 1 | Citations (PDF) |
| 60 | Type I IFN Contributes to NK Cell Homeostasis, Activation, and Antitumor Function | 0.6 | 304 | Citations (PDF) |
| 61 | ABIN-3: a Molecular Basis for Species Divergence in Interleukin-10-Induced Anti-Inflammatory Actions | 2.5 | 56 | Citations (PDF) |
| 62 | A Novel c-Jun-dependent Signal Transduction Pathway Necessary for the Transcriptional Activation of Interferon γ Response Genes | 2.2 | 57 | Citations (PDF) |
| 63 | Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? | 5.3 | 281 | Citations (PDF) |
| 64 | Cancer Immunosurveillance and Immunoediting: The Roles of Immunity in Suppressing Tumor Development and Shaping Tumor Immunogenicity | 7.1 | 733 | Citations (PDF) |
| 65 | Blocking Monoclonal Antibodies Specific for Mouse IFN-α/βReceptor Subunit 1 (IFNAR-1) from Mice Immunized byIn VivoHydrodynamic Transfection | 1.7 | 249 | Citations (PDF) |
| 66 | Perforin and Granzymes Have Distinct Roles in Defensive Immunity and Immunopathology | 23.3 | 146 | Citations (PDF) |
| 67 | Interferons, immunity and cancer immunoediting | 56.7 | 1,426 | Citations (PDF) |
| 68 | Novel STAT1 Alleles in Otherwise Healthy Patients with Mycobacterial Disease | 3.3 | 180 | Citations (PDF) |
| 69 | NF-κB-Inducing Kinase Regulates Selected Gene Expression in the Nod2 Signaling Pathway | 2.7 | 49 | Citations (PDF) |
| 70 | IFN-Dependent Down-Regulation of the NKG2D Ligand H60 on Tumors | 0.6 | 98 | Citations (PDF) |
| 71 | Bone Marrow Stromal Cell Antigen 2 Is a Specific Marker of Type I IFN-Producing Cells in the Naive Mouse, but a Promiscuous Cell Surface Antigen following IFN Stimulation | 0.6 | 405 | Citations (PDF) |
| 72 | Interferon-γ and Cancer Immunoediting | 2.8 | 131 | Citations (PDF) |
| 73 | Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations | 26.1 | 206 | Citations (PDF) |
| 74 | A critical function for type I interferons in cancer immunoediting | 24.2 | 564 | Citations (PDF) |
| 75 | IFN-γ Controls the Generation/Activation of CD4+CD25+ Regulatory T Cells in Antitumor Immune Response | 0.6 | 95 | Citations (PDF) |
| 76 | Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity | 24.2 | 261 | Citations (PDF) |
| 77 | The Three Es of Cancer Immunoediting | 30.0 | 2,668 | Citations (PDF) |
| 78 | The Immunobiology of Cancer Immunosurveillance and Immunoediting | 23.3 | 2,759 | Citations (PDF) |
| 79 | The IκB Function of NF-κB2 p100 Controls Stimulated Osteoclastogenesis | 9.4 | 269 | Citations (PDF) |
| 80 | Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice | 10.7 | 230 | Citations (PDF) |
| 81 | STAT1 deficiency unexpectedly and markedly exacerbates the pathophysiological actions of IFN- in the central nervous system | 7.6 | 63 | Citations (PDF) |
| 82 | The roles of IFNγ in protection against tumor development and cancer immunoediting | 10.8 | 856 | Citations (PDF) |
| 83 | Stat1-dependent and -independent pathways in IFN-γ-dependent signaling | 10.6 | 565 | Citations (PDF) |
| 84 | Cancer immunoediting: from immunosurveillance to tumor escape | 24.2 | 4,738 | Citations (PDF) |
| 85 | A completely foreign receptor can mediate an interferon-gamma-like response | 7.4 | 30 | Citations (PDF) |
| 86 | ERK1 and ERK2 Activate CCAAAT/Enhancer-binding Protein-β-dependent Gene Transcription in Response to Interferon-γ | 2.2 | 155 | Citations (PDF) |
| 87 | Biologic consequences of Stat1-independent IFN signaling | 7.6 | 344 | Citations (PDF) |
| 88 | Stat1-independent regulation of gene expression in response to IFN- | 7.6 | 241 | Citations (PDF) |
| 89 | Stat-1 Is Not Essential for Inhibition of B Lymphopoiesis by Type I IFNs | 0.6 | 32 | Citations (PDF) |
| 90 | Partial Interferon‐γ Receptor Signaling Chain Deficiency in a Patient with Bacille Calmette‐Guérin andMycobacterium abscessusInfection | 3.8 | 175 | Citations (PDF) |
| 91 | Eradication of Established Tumors by CD8+ T Cell Adoptive Immunotherapy | 23.3 | 326 | Citations (PDF) |
| 92 | Measurement of Mouse and Human Interferon γ | 2.6 | 8 | Citations (PDF) |
| 93 | CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN- | 7.6 | 339 | Citations (PDF) |
| 94 | Interleukin-10 Receptor Signaling through the JAK-STAT Pathway | 2.2 | 360 | Citations (PDF) |
| 95 | Reversal of virus-induced systemic shock and respiratory failure by blockade of the lymphotoxin pathway | 39.5 | 62 | Citations (PDF) |
| 96 | A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection | 26.1 | 474 | Citations (PDF) |
| 97 | Type I interferons are essential mediators of apoptotic death in virally infected cells | 1.5 | 147 | Citations (PDF) |
| 98 | Disruption of the Jak1 Gene Demonstrates Obligatory and Nonredundant Roles of the Jaks in Cytokine-Induced Biologic Responses | 34.1 | 824 | Citations (PDF) |
| 99 | HOW CELLS RESPOND TO INTERFERONS | 17.7 | 3,697 | Citations (PDF) |
| 100 | Functional Cooperation of the Interleukin-2 Receptor β Chain and Jak1 in Phosphatidylinositol 3-Kinase Recruitment and Phosphorylation | 2.5 | 54 | Citations (PDF) |
| 101 | Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice | 7.6 | 1,346 | Citations (PDF) |
| 102 | Synergy between Interferon-γ and Tumor Necrosis Factor-α in Transcriptional Activation Is Mediated by Cooperation between Signal Transducer and Activator of Transcription 1 and Nuclear Factor κB | 2.2 | 393 | Citations (PDF) |
| 103 | Ligand-induced Formation of p55 and p75 Tumor Necrosis Factor Receptor Heterocomplexes on Intact Cells | 2.2 | 73 | Citations (PDF) |
| 104 | The molecular basis of IFNγ action | 0.2 | 1 | Citations (PDF) |
| 105 | Chronic Tumor Necrosis Factor Alters T Cell Responses by Attenuating T Cell Receptor Signaling | 9.4 | 276 | Citations (PDF) |
| 106 | THE IFNγ RECEPTOR:A Paradigm for Cytokine Receptor Signaling | 30.0 | 981 | Citations (PDF) |
| 107 | Targeted Disruption of the Stat1 Gene in Mice Reveals Unexpected Physiologic Specificity in the JAK–STAT Signaling Pathway | 34.1 | 1,587 | Citations (PDF) |
| 108 | The Future of Immunity | 23.3 | 0 | Citations (PDF) |
| 109 | Identification of an Interferon-γ Receptor α Chain Sequence Required for JAK-1 Binding | 2.2 | 95 | Citations (PDF) |
| 110 | Ligand-Induced Assembly and Activation of the Gamma Interferon Receptor in Intact Cells | 2.5 | 132 | Citations (PDF) |
| 111 | Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors | 3.2 | 135 | Citations (PDF) |
| 112 | Regulation of IFN‐α/β genes: evidence for a dual function of the transcription factor complex ISGF3 in the production and action of IFN‐α/β | 1.5 | 90 | Citations (PDF) |
| 113 | Stat3 Recruitment by Two Distinct Ligand-induced, Tyrosine-phosphorylated Docking Sites in the Interleukin-10 Receptor Intracellular Domain | 2.2 | 198 | Citations (PDF) |
| 114 | Stat recruitment by tyrosine-phosphorylated cytokine receptors: An ordered reversible affinity-driven process | 23.3 | 283 | Citations (PDF) |
| 115 | Tissue-specific targeting of gytokine unresponsiveness in transgenic mice | 23.3 | 85 | Citations (PDF) |
| 116 | Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFNγ receptors | 23.3 | 580 | Citations (PDF) |
| 117 | The biology and biochemistry of interferon-gamma and its receptor | 0.0 | 21 | Citations (PDF) |
| 118 | IFN-γ produced in vivo during the first two days is critical for resolution of murine Leishmania major infections | 3.3 | 16 | Citations (PDF) |
| 119 | Monoclonal anti-tumor necrosis factor antibody renders non-obese diabetic mice hypersensitive to irradiation and enhances insulitis development | 3.2 | 45 | Citations (PDF) |
| 120 | The structure and function of interferon-γ receptors | 1.3 | 17 | Citations (PDF) |
| 121 | HBsAg retention sensitizes the hepatocyte to injury by physiological concentrations of interferon-γ | 10.6 | 148 | Citations (PDF) |
| 122 | Characterization and expression of the human leukocyte-common antigen (CD45) gene contained in yeast artificial chromosomes | 2.8 | 18 | Citations (PDF) |
| 123 | Natural Immunity: A T‐Cell‐Independent Pathway of Macrophage Activation, Defined in the scid Mouse | 6.6 | 324 | Citations (PDF) |
| 124 | Cytokine‐related syndrome following injection of anti‐CD3 monoclonal antibody: Further evidence for transient <i>in vivo</i> T cell activation | 3.2 | 261 | Citations (PDF) |
| 125 | Enumeration of cytokine-secreting cells at the single-cell level | 3.2 | 25 | Citations (PDF) |
| 126 | PREVENTION OF THE GRAFT-VERSUS-HOST REACTION IN NEWBORN MICE BY ANTIBODIES TO TUMOR NECROSIS FACTOR-ALPHA | 1.2 | 62 | Citations (PDF) |
| 127 | Up-Regulation of Gamma Interferon Receptors on the Human Monocytic Cell Line U937 by 1,25-Dihydroxyvitamin D3 and Granulocyte-Macrophage Colony Stimulating Factor | 3.0 | 19 | Citations (PDF) |
| 128 | Macrophage activation factor from EL-4, a murine T-cell line: Antigenic characterization by hamster monoclonal antibodies to murine interferon-γ | 2.6 | 3 | Citations (PDF) |
| 129 | Deficiency of erythrocyte C3b receptor (CR1) in AIDS and AIDS-related syndromes | 4.0 | 9 | Citations (PDF) |
| 130 | Leprosy: Altered Complement Receptors in Disseminated Disease | 2.3 | 20 | Citations (PDF) |
| 131 | Rapid induction of the expression of proto-oncogene fos during human monocytic differentiation | 34.1 | 424 | Citations (PDF) |
| 132 | Macrophage I-A/I-E expression and macrophage-stimulating lymphokines in murine lupus | 2.6 | 36 | Citations (PDF) |
| 133 | The chemistry and biology of complement receptors | 4.0 | 60 | Citations (PDF) |
| 134 | The role of C3 fragments in endocytosis and extracellular cytotoxic reactions by polymorphonuclear leukocytes | 1.9 | 71 | Citations (PDF) |
| 135 | Identification of the Activator System for Antibody to Toxoplasma as the Classical Complement Pathway | 3.8 | 63 | Citations (PDF) |
| 136 | Raji cell injury and subsequent lysis by the purified cytolytic alternative pathway of human complement | 1.9 | 63 | Citations (PDF) |
| 137 | FOURTH COMPONENT OF HUMAN COMPLEMENT: DESCRIPTION OF A THREE POLYPEPTIDE CHAIN STRUCTURE | 9.4 | 193 | Citations (PDF) |
